Phase Ib/IIa Open-label Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced Solid Tumors, including Pancreatic Cancer
Summary
The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors:
- Safety and tolerability of NT-I7 in combination with pembrolizumab
- Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D)
The main purpose of Phase 2a of this study is to assess the preliminary anti-tumor activity of NT-I7 in combination with pembrolizumab in participants with checkpoint inhibitor (CPI) treated and naïve relapsed and refractory tumors.
General Information
NCT#: NCT04332653
Study ID: NIT-110 (PNA60)
Trial Phase: Phase I/II
Trial Sponsor: NeoImmuneTech Inc.
Therapies Used in This Trial: Pembrolizumab, NT-I7